At 6.0% CAGR, the Europe Diabetic Foot Ulcer Market is projected to be worth US$ 2,924.75 million by 2030, says Business Market Insights.

According to Business Market Insights' research, the Europe diabetic foot ulcer market was valued at US$ 1,837.31 in 2022 and is expected to reach US$ 2,924.75 million by 2030, registering a CAGR of 6.0% from 2022 to 2030. Use of 3D printing in wound care management is among the critical factors attributed to the Europe diabetic foot ulcer market expansion.

Skin tissue damage caused by various indications due to diabetes and vascular diseases significantly burdens the healthcare systems. 3D bioprinting is based on layer-based synthesis, wherein the newly generated cells and cell-based materials can be dispensed to mimic native tissues. Though the technology is still nascent, 3D printing can potentially revolutionize the wound care industry. Many companies are involved in developing new products involving ion-release biomaterials that promote angiogenesis for dermal regeneration. In addition, 3D bioprinting helps patch large wounds that are hard to heal with standard techniques. Thus, the use of 3D bioprinting technologies in ulcer or wound treatments is likely to emerge as a prominent trend in the diabetic foot ulcer market in the coming years.

On the contrary, high cost of advanced wound care treatments hamper the growth Europe diabetic foot ulcer market.

Based on treatment type, the Europe diabetic foot ulcer market is segmented into advanced wound care dressings, therapy device, and biologics. The advanced wound care dressings segment held 56.3% share of the Europe diabetic foot ulcer market in 2022, amassing US$ 1,034.70 million. It is projected to garner US$ 1,674.36 million by 2030 to expand at 6.2% CAGR during 2022-2030.

Based on ulcer type, the Europe diabetic foot ulcer market is segmented into neuro-lschemic ulcers, neuropathic ulcers, and ischemic ulcers. The neuro-lschemic ulcers segment held 54.4% share of the Europe diabetic foot ulcer market in 2022, amassing US$ 999.69 million. It is projected to garner US$ 1,626.16 million by 2030 to expand at 6.3% CAGR during 2022–2030.

Based on infection severity, the Europe diabetic foot ulcer market is segmented into mild, moderate, and severe. The moderate segment held 48.7% share of Europe diabetic foot ulcer market in 2022, amassing US$ 893.90 million. It is projected to garner US$ 1,467.64 million by 2030 to expand at 6.4% CAGR during 2022–2030.

Based on end user, the Europe diabetic foot ulcer market is segmented into hospitals, ambulatory surgical centers, and home care. The hospitals segment held 55.6% share of Europe diabetic foot ulcer market in 2022, amassing US$ 1,021.25 million. It is projected to garner US$ 1,685.07 million by 2030 to expand at 6.5% CAGR during 2022–2030.

Based on country, the Europe diabetic foot ulcer market is segmented into Germany, France, UK, Italy, Spain, and the Rest of Europe. Germany held 29.9% share of Europe diabetic foot ulcer market in 2022, amassing US$ 548.44 million. It is projected to garner US$ 925.68 million by 2030 to expand at 6.8% CAGR during 2022–2030.

Key players operating in the Europe diabetic foot ulcer market are Convatec Group Plc, 3M Co, Coloplast AS, Smith & Nephew Plc, B. Braun SE, Medline Industries LP, Organogenesis Inc., Mölnlycke Health Care AB, and MiMedx Group Inc, among others.

• In Jan 2023, Convatec announced the launch of ConvaFoam, a family of advanced foam dressings designed to address the needs of healthcare providers and their patients. ConvaFoam can be used on a spectrum of wound types at any stage of the wound journey, making it the simple dressing choice for wound management and skin protection.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com